Abstract
Interstitial iung processes are a heterogeneous group of diseases with different etiopathogeneses. Progressive pulmonary fibrosis includes diverse nosological units, the common feature of which is a progressive phenotype.
The progressive pulmonary (PPF) fibrosis phenotype is associated with poor prognosis, higher risk of acute exacerbations, and increased mortality. Idiopathic pulmonary fibrosis (IPF) is a typical prototype of PPF with a poor prognosis and high mortality.
Among the treatment options available to patients with IPF and PPF is antifibrotic therapy, which slows the progression of the disease. However, despite Bronchogenic carcinoma has a high incidence and mortality rate in the Czech Republic and worldwide.
It is an aggressive neuroendocrine tumour characterised by early and multiple metastases that require rapid treatment, otherwise survival of patients is in the range of weeks to months. Although there have been explosive advances in pharmacotherapy for non-small cell lung cancer over the past 20 years, we have had no new therapeutic arsenal for small cell carcinoma.
Targeted therapy for this type of tumor is not in sight. In recent years, ongoing trials with immunotherapy have given us some hope, and 2022 has also become a turning point in terms of reimbursement for immunotherapy.
However, we still need to bear in mind that small cell carcinoma of the lung remains a disease with a poor prognosis.all available treatment options, high mortality rate remains. A comprehensive approach to patients is necessary, keeping in mind timely referrals centers for Interstitial lung processes, precise diagnostics, and consultations within multidisciplinary teams.